| Naslov: | PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy |
|---|
| Avtorji: | ID Vrankar, Martina (Avtor)
ID Zwitter, Matjaž (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
ID Stanič, Karmen (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite http://www.elis.sk/download_file.php?product_id=5518&session_id=kocugv6art3ltib4t6te7tjam3
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of 15%, therefore new treatment strategies, including immunotherapy, are under investigation, with programmed death ligand-1 (PD-L1) as one of the major players. We evaluated the clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 and correlated their expression with clinicopathological parameters and outcome of treatment. Among 107 patients treated with concurrent CRT, a total of 43 (36 males and 7 females) had sufficient tissue for immunohistochemical (IHC) staining. The expression of PD-L1 was demonstrated in 7 tumors, in 6 males and 1 female. No statistical significant differences in patient characteristics, including age, smoking status and gender, were found according to the PD-L1 expression. After a median follow up of 103.6 months, median progression free survival (PFS) was 19.9 months in patients without and 10.1 months in patients with PD-L1 expression (p=0.008). Median overall survival (OS) was 28.4 and 12.1 months for PD-L1 negative and PD-L1 positive patients, respectively (p=0.012). In conclusions, patients with PD-L1 expression had shorter PFS and OS after concurrent CRT in LA NSCLC. Unfortunately, only small number of patients had tissue available for the IHC testing, therefore no firm conclusions could be made and further investigation is warranted. |
|---|
| Ključne besede: | non-small cell lung cancer, lung cancer, chemoradiotherapy, survival |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Kraj izida: | Slovaška |
|---|
| Založnik: | AEPress |
|---|
| Leto izida: | 2018 |
|---|
| Št. strani: | str. 140-146 |
|---|
| Številčenje: | Vol. 65, no. 1 |
|---|
| PID: | 20.500.12556/DiRROS-12920  |
|---|
| UDK: | 616.2 |
|---|
| ISSN pri članku: | 0028-2685 |
|---|
| DOI: | 10.4149/neo_2018_170206N77 |
|---|
| COBISS.SI-ID: | 2806907 |
|---|
| Datum objave v DiRROS: | 17.12.2020 |
|---|
| Število ogledov: | 1338 |
|---|
| Število prenosov: | 420 |
|---|
| Metapodatki: |     |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
